Bergen, Norway, 11 August 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, will announce its results for the second quarter and half year 2017 on Friday, 18 August 2017. A presentation by BerGenBio’s senior management team will take place at 10.00 am CET at: Thon … Read more
Bergen, Norway, July 26 2017 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focussed on developing novel, selective AXL kinase inhibitors for multiple cancer indications, is pleased to announce that Murray Yule, MD, PhD, Clinical Development Officer at BerGenBio, will present an outline of the phase II clinical development programme of BerGenBio’s lead product, BGB324, … Read more
Bergen, Norway, 13 July 2017. Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 27 June 2017 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the exercise options pursuant to the Company’s … Read more
Bergen, Norway, 27 June 2017. Participants in BerGenBio ASA’s (the “Company”) (OSE: BGBIO) employee share option program, not being primary insiders, have exercised a total number of 15,000 options with a strike price of NOK 10.6172. Each option gives the right to receive one share in the Company. The Board of Directors of the Company … Read more
Bergen, Norway, June 26 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, is pleased to announce the award of a NOK 24 million (USD 2.85m) grant from Innovasjon Norge to support the clinical development of BGB324 in combination with Merck & Co.’s KEYTRUDA® (pembrolizumab) in … Read more
Bergen, Norway, June 6 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class Axl kinase inhibitors to treat multiple cancer indications, reported encouraging clinical and in vitro data with its lead, first-in-class Axl inhibitor, BGB324 in patients with high-risk Myeloid Dysplastic Syndrome (MDS) in a poster presentation at the American Society … Read more
Bergen, Norway, 23 May 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces its results for the first quarter 2017. A presentation of the results by the company’s senior management team will take place today at 10:00a.m. CET in Oslo – details below. Richard Godfrey, … Read more
Bergen, Norway, May 22 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications, announces that the first patients have been dosed and continue on therapy in a Phase I/II randomised trial evaluating the addition of BerGenBio’s highly selective, potent and … Read more
Bergen, Norway, May, 19 2017 – Leading oncology biopharmaceutical company BerGenBio ASA, announces that its first-in-class small molecule Axl inhibitor BGB324 will be featured in a poster presentation at the upcoming 2017 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL from June 2-6, 2017. The presentation will focus on pre-clinical as well … Read more
Bergen, Norway, 16 May 2017: BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, will announce its results for the first quarter 2017 on Tuesday, 23 May 2017. A presentation by BerGenBio’s senior management team will take place at 10:00 am CET at: Thon Hotel Vika Atrium, Munkedamsveien … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.